go to main content

Overview of research groups connected to RIMLS. You can filter the list with regards to research theme and research department.

Results (22)

Filter results

Cancer genomics

Richarda de Voer's research group focuses on the discovery of novel genetic variants that predispose to cancer and the investigation of the molecular pathways via which these variants initiate carcinogenesis.

Chemical immunology

Carl Figdor's research group studies chemical biology with a focus on the targeting of Dendritic Cells and a focus on developing synthetic Dendritic Cells to directly activate T cells.

Dendritic cell vaccination

Jolanda de Vries's research group focuses on dendritic cell vaccination. Dendritic Cell (DC) therapy represents a promising immunotherapeutic approach for the treatment of cancer.

Developmental epigenomics

Jo Zhou's group aims to establish disease models using patient material and model organisms to identify regulatory networks and disease mechanisms in developmental disorders. Using genomics technology, we map the genome-wide atlas of disease-associated regulatory elements beyond the coding regions.

Experimental virology

Ronald van Rij's group studies virus-host interactions in both mosquito vector and mammalian host. By doing so, we hope to gain insights into arbovirus transmission and contribute to the development of novel antiviral therapy.

Genome bioinformatics

Developing and applying bioinformatics methods to gain insight into the causes and mechanisms of genetic disorders such as intellectual disability.

Human papillomaviruses (HPV)

Willem Melchers' research aims to improve the nationwide cervical cancer screening, with the possibility of using self sampling. Important herein is research on the use of new triage methods for hrHPV positive women, by using HPV genotyping or molecular biomarkers.

Immune cell signaling

Annemiek van Spriel's research group aims to understand how immune cells physically organize and compartmentalize signaling molecules into efficient, regulated membrane-proximal signaling complexes.

Immuno-Genomics

Alexander Hoischen's group focuses on the application of latest genomic technologies to understand human disease. A particular emphasis is put in the understanding of genetic defects that explain immune diseases, in particular primary immunodeficiencies (PIDs).

Ion channels and calcium signaling: a matter of structure, function, and regulation

Jenny van der Wijst's research group works on the regulation of epithelial calcium transport, with a fundamental focus on the electrophysiological analysis combined with the biochemistry of ion channels and cell signaling.

Magnesium in health and disease

Jeroen de Baaij's research group examines the role of magnesium in health and disease. Our team studies the regulation of magnesium handling by the intestine and the kidney, as well as the role of magnesium in disease including diabetes mellitus type 2 and chronic kidney disease.

Malaria parasites

Robert Sauerwein's group focuses on the clinical development of plasmodium falciparum vaccines for control and elimination of malaria.

Membrane trafficking

Geert van den Bogaart's research group aims to understand and ultimately tailor membrane trafficking pathways in immune cells.

Molecular biology of ciliopathies

Ronald Roepman's group aims to generate detailed parts lists of the molecular machines that are active in the cilia, and identify either their structural role in the cilium, or their role in the signaling pathways that are dependent on/directed by cilia.

Multiscale Imaging

Mangala Srinivas's research group focuses on new types of contrast agents for multiple types of imaging.

Mycology

Paul Verweij's research group is primarily focused on fungal infections. We aim to develop methods for rapid and reliable identification of fungal infections in order to start early treatment and therefore improve the outcome for patients.

Outcome measures in mitochondrial disease

Saskia Koene's research group aims to select the most robust outcome measures to follow the health status of patients. Robust outcome measures are essential to monitor the natural disease course and to explore the effect of interventions.

Patient cohorts and clinical trials in mitochondrial disease

Mirian Janssen's research group collects clinical, biochemical and genetic information of patients in order to convert scientific advances into benefits for patients with mitochondrial disease.

Polycystic liver disease

Joost Drenth's group aims to discover novel paradigms for effective treatment of patients. Our strategy starts with disease gene discovery followed by functional studies to understand cellular pathogenesis. The main focus is polycystic liver disease, a rare inherited liver disorder.

Renal electrolyte handling

René Bindels' research group studies the regulation of ion transport processes in kidney and small intestine in health and disease. Current projects involve the molecular mechanisms underlying rare tubulopathies and the regulation of the newly identified calcium, magnesium and sodium transporters.

Tumor micro­environment

Carl Figdor's research group tries to develop novel prognostic and predictive biomarkers, by studying tumor and blood samples from patients treated with dendritic cell (DC) vaccines. An in vitro 3D-Skin model was built to systematically study tumor- microenvironment interactions.

Understanding tubulopathies

Joost Hoenderop's group focuses on tubular transport of calcium, magnesium and sodium by the kidney tubule and the changes therein. For acquired renal disorders, uncovering the underlying mechanism, prevention and rational treatments for drug-induced toxicities is a main focus.

login